

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Gocovri ER (amantadine extended release)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

**Maryland Medicaid – See State Specific Mandates below*

Medications	Quantity Limit
Gocovri ER (amantadine extended release)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Gocovri ER (amantadine extended release) may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of amantadine immediate release (AAN 2006, Movement Disorder Society 2011); **AND**
- II. Documentation has been provided for why the extended release agent is clinically necessary and not for convenience; **AND**
- III. Individual is 18 years of age or older; **AND**
- IV. Individual has been diagnosed with Parkinson's Disease; **AND**
- V. Individual is receiving levodopa based therapy (with or without concomitant dopaminergic agents); **AND**
- VI. Individual is using to treat dyskinesia.

Requests for Gocovri ER (amantadine extended release) may not be approved for the following:

- I. Individual has end-stage renal disease (EGFR < 15 mL/min/1.73 m²).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
Maryland Medicaid		Trial of IR amantadine is not required

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*. 2013;81:463-9. Available at <https://www.aan.com/Guidelines/>. Accessed April 13, 2017.
6. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. *Mov Disord* 2011; 26(suppl 3):S2-S41

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0305-18